A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.

By O. Rascol, D. Brooks, A. Korczyn, D. Pp, C. Clarke, A. Lang. New England Journal of Medicine, 2000

1,545 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/0b003562258adaaa1ce99ac3326424ca08c8e7e1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

Citations in the corpus

Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease (2011, result): “The same was observed in clinical trials where compared with L-DOPA monotherapy in early PD, ropinirole, pramipexole, cabergoline and pergolide produced a lower incidence of dyskinesia in the first 4–5 years of treatment (Parkinson Study Group, 2000; Rascol et al., 2000; Hubble, 2002; Oertel et al.,”
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study (2003, methodology): “The use of (18)F-dopa PET to assess the effects of ropinirole on disease progression was recently assessed in a pilot study(21,22) involving a 45-patient subgroup of a large clinical study,(23) where patients with early PD were randomized 2 to 1 to receive either ropinirole or L-dopa.(23) After 2 ye”
Characterization of freezing of gait subtypes and the response of each to levodopa in Parkinson's disease (2003, background): “Recent studies have suggested that DA may increase FOG frequency, especially in the early stages of PD (Ahlskog et al., 1992; Parkinson Study Group, 2000; Rascol et al., 2000) as well as in later more advanced stages (Wiener et al.”
Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease (2002, background): “…31 May 2001, revised 2 October 2001, accepted 8 November 2001 latter compound is the prototype of a class of antiparkinsonian drugs which do not induce dyskinesia when administered de novo (Rascol et al., 1979; Lees & Stern, 1981; BeÂdard et al., 1986; Pearce et al., 1998; Rascol et al., 2000).”
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. (2004, result): “The observation that the development of freezing was more common in the pramipexole group than in the levodopa group has been previously reported for other dopamine agonists.(14) In the ropinirole trial, 57 (32%) of 178 subjects in the ropinirole group and 22 (25%) of 88 subjects in the levodopa gro”
Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. (2000, background): “…reported in the literature vary greatly, ranging from levodopa), compared with those treated with levodopa from the outset (20 versus 45%, P 0.0001; Rascol et al., 2000).19 to 80% of patients experiencing fluctuations after 5 or 6 years of treatment with levodopa (Poewe et al., 1986; In another…”
The cerebellum in Parkinson’s disease (2013, background): “Chronic dopamine replacement therapy in patients with Parkinson’s disease is commonly complicated by involuntary movements known as levodopa-induced dyskinesia (Fahn, 2000; Rascol et al., 2000).”
Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. (2000, result): “Two reports have shown a reduced incidence of dyskinesias by initiating treatment with dopamine agonists ropinirole or cabergoline compared with levodopa.(3,4) The ropinirole trial found no statistical differences in the occurrences of adverse events or in changes in the activities of daily living (”